Merrill Lynch 4 Top Pharmaceutical Dividend Stocks To Own For 2016

While pricing and cost concerns won’t go away completely until the election cycle winds down, now may be an ideal time to add the top yielding stocks to portfolios for 2016. 24/7 Wall St. has screened the Merrill Lynch research universe for the top pharmaceutical stocks that are rated as Buy at the company that also which also pay investors solid dividends. The companies we found have long histories of paying and raising their dividends, and make good sense for conservative growth and income portfolios.

This is a top pharmaceutical stock with very solid growth potential. Abbott Laboratories (NYSE: ABT) is a leading diversified global healthcare company that develops, manufactures and markets branded generics, medical devices, nutritional products, and diagnostic solutions. Eli Lilly and Company (NYSE: LLY) is a global healthcare company with numerous core products in a number of primary-care pharmaceutical markets. Merck & Co. Inc. (NYSE: MRK) sells numerous prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, are provided to customers in more than 140 countries. Pfizer Inc. (NYSE: PFE) has a very strong pipeline and the fact that Pfizer is the world’s largest drug manufacturer by sales value.

Source: Wall St.24/7

Related Articles:
- 8 Dividend Stocks With The Right Stuff
- 6 Dividend Stocks Trading at a Double-Digit Discount
- 5 Best U.S. Dividend Growth Stocks
- 5 Low P/E Value-Stocks, Yielding 2% Or Higher
- How Much Money Will You Need To Retire?